Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

Exclusion criteria

• 1. Current diagnosis of other drug or alcohol dependence (excluding nicotine) 2. significant cardiac disease as indicated by history or suspected by abnormal ECG or history of cardiac symptoms 3. Positive and Negative Syndrome Scale (PANSS) subscale for positive symptoms of psychosis item \> 3 (moderate) at baseline evaluation 4. current medical condition that could prevent regular study attendance 5. liver function tests \>3 times the upper limit of normal range 6. history of seizure disorder or history of head trauma or CNS insult that could predispose the subject to seizures 7. taking clozapine 8. current suicidal risk 9. bradycardia less than or equal to 50 bpm, supine blood pressure of less than or equal to 100/65, a seated blood pressure of less than or equal to 90/60, or orthostatic change of \>20 systolic or \>10 diastolic on standing, at screening or any pre-dose assessment, or symptoms attributable to low BP (i.e. lightheadedness or dizziness on standing) 10. mental retardation or organic mental disorder 11. currently in a residential treatment setting in which substance use is monitored and restricted, since the restricted access to drugs could represent an important confounding variable 12. pregnant, nursing, or, if a woman of childbearing potential, not using a form of birth control judged by the investigator to be effective 13. concomitant treatment with opioid analgesics, sedative hypnotics, or other known CNS depressants 14. known hypersensitivity to cannabinoids or sesame oil or clonidine 15. disease of the gastrointestinal system, liver, or kidneys that may impede metabolism or excretion of dronabinol 16. inability to read or write in English that would hinder their ability to follow study procedures 17. history of seizures or a family history of seizures.